Healthcare · Drug Manufacturers - Specialty & Generic
Price
$0.88
Market Cap
$2.8M
Employees
35
Beta
4.97
Avg Volume
207,266
CEO
Dror Ben-Asher
Business Description
RedHill Biopharma Ltd. is a specialized pharmaceutical firm concentrating its efforts mainly on therapies for digestive tract conditions and various infections. The company markets several gastrointestinal medications: Movantik, which addresses opioid-induced constipation in adults experiencing chronic non-cancer pain; Talicia, used to treat Helicobacter pylori infections in adult patients; and Aemcolo, prescribed for adults suffering from travelers' diarrhea. Its robust late-stage clinical pipeline features several promising investigational compounds. RHB-204 is currently in Phase 3 for pulmonary nontuberculous mycobacteria infections. Opaganib (Yeliva), an SK2 selective inhibitor, has completed Phase 2 for severe SARS-CoV-2 related COVID-19 pneumonia, is in Phase 2 for advanced unresectable cholangiocarcinoma, and is also being investigated in a researcher-sponsored Phase 2 study for prostate cancer. RHB-107 is progressing through Phase 2/3 trials for COVID-19 outpatients, is undergoing preclinical evaluation for advanced unresectable cholangiocarcinoma, and has successfully concluded Phase 2 studies for gastrointestinal and other solid tumors. Furthermore, RHB-104 is in Phase 3 development for Crohn's disease. RHB-102 (Bekinda) is also in Phase 3 for acute gastroenteritis and gastritis, following its successful completion of Phase 2 for irritable bowel syndrome with diarrhea. Lastly, RHB-106, an encapsulated formulation designed for bowel preparation, is preparing to commence Phase 2/3 clinical studies. Established in 2009, RedHill Biopharma Ltd. maintains its headquarters in Tel Aviv, Israel.
Business History
Price Overview
Last updated: Jun 27, 2026 10:07am (just now)$0.88
+0.02 (+2.15%)
Day Range
$0.86 – $0.94
52-Week Range
$0.71 – $3.31
50-Day MA
$0.95
200-Day MA
$1.16
Volume
72,603.00
Share Structure
Outstanding
3,142,857.00
Float
2,280,394.00
Free Float
72.6%
Normal free float
— 72.6% of shares trade freely, ~27.4% held by insiders/institutions
Healthy float typical of established companies. Good liquidity for entering and exiting positions without major price impact.
Small absolute float (2.3M shares) — even with a decent free float %, volume can be thin. Check average daily volume before sizing a position.
Price History (1 Year)
Revenue & Net Income Trend
The directional story — useful even when net income is negative.
Revenue
The top line — total sales before any costs or taxes are subtracted. A measure of how much business the company is doing.
Net Income
The bottom line — profit left after subtracting all expenses, interest, and taxes from revenue. Reflects accounting profitability, but includes non-cash items like depreciation, so it isn't the same as cash earned.
Operating Cash Flow
The real cash generated by the day-to-day business — selling products, paying suppliers, collecting from customers. Calculated from net income by adding back non-cash items and adjusting for timing (unpaid bills, unsold inventory). When OCF consistently lags net income, the reported profit may not be converting to real money.
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
API Direct from provider
CALC Derived from statements
P/E Ratio (Price per dollar of earnings)
Stock Price / EPS (Diluted)
—
Stock Price: $0.88
EPS (Diluted): 0.00
EPS (Diluted): 0.00
EPS is zero — cannot divide
P/B Ratio (Price vs net asset value)
APIStock Price / Book Value Per Share
0.76
Stock Price: $0.88
Total Equity: $4.27M
Shares: 3,159,175
Total Equity: $4.27M
Shares: 3,159,175
EV/EBITDA (Total value vs operating profit)
APIEnterprise Value / EBITDA
0.02
Market Cap: $2.76M
Total Debt: $0.00
Cash: $3.97M
EBITDA: -$7.65M
Total Debt: $0.00
Cash: $3.97M
EBITDA: -$7.65M
Enterprise Value (Takeover price (cap + debt - cash))
APIMarket Cap + Total Debt - Cash
$352,950
Market Cap: $2.76M
Total Debt: $0.00
Cash: $3.97M
Total Debt: $0.00
Cash: $3.97M
P/S Ratio (Price per dollar of revenue)
APIStock Price / Revenue Per Share
11.38
Stock Price: $0.88
Revenue: $286,000
Shares: 3,159,175
Revenue: $286,000
Shares: 3,159,175
EV/Sales (Total value vs revenue — works when P/E can't)
API1.23
Gross Margin (Revenue left after direct costs)
APIGross Profit / Revenue
100.0%
Gross Profit: $286,000
Revenue: $286,000
Revenue: $286,000
Operating Margin (Revenue left after all operations)
APIOperating Income / Revenue
-2,765.4%
Operating Income: -$7.91M
Revenue: $286,000
Revenue: $286,000
Net Margin (Revenue left as actual profit)
APINet Income / Revenue
-150.0%
Net Income: -$429,000
Revenue: $286,000
Revenue: $286,000
ROE (Profit from shareholder equity)
APINet Income / Total Equity
291.1%
Net Income: -$429,000
Total Equity: $4.27M
Total Equity: $4.27M
ROIC (Profit from all invested capital)
APINOPAT / Invested Capital
-118.5%
Operating Income: -$7.91M
Tax Rate: 0.0%
Equity: $4.27M
Total Debt: $0.00
Cash: $3.97M
Tax Rate: 0.0%
Equity: $4.27M
Total Debt: $0.00
Cash: $3.97M
Zero debt — invested capital = equity minus cash (very efficient)
Current Ratio (Can it pay short-term bills)
APICurrent Assets / Current Liabilities
0.34
Current Assets: $6.53M
Current Liabilities: $19.22M
Current Liabilities: $19.22M
Debt/Equity (Leverage — debt vs equity)
CALCTotal Debt / Total Equity
0.00
Short-Term Debt: $0.00
Long-Term Debt: $0.00
Total Debt: $0.00
Total Equity: $4.27M
Long-Term Debt: $0.00
Total Debt: $0.00
Total Equity: $4.27M
Zero debt — this company carries no debt obligations. Strongest possible score.
Rev/Share (Top-line per share)
CALCRevenue / Shares Outstanding
$0.09
Revenue: $286,000
Shares: 3,159,175
Shares: 3,159,175
Book Value/Share (Net assets per share)
CALC(Total Assets - Total Liabilities) / Shares
$1.35
Total Equity: $4.27M
Shares: 3,159,175
Shares: 3,159,175
FCF/Share (Real cash generated per share)
CALC(Operating Cash Flow + CapEx) / Shares
$-3.06
Operating CF: -$9.65M
CapEx: -$5,000
Shares: 3,159,175
CapEx: -$5,000
Shares: 3,159,175
CapEx is negative (outflow) — added to OCF to get FCF
Div Yield (Annual income from holding)
APILast Annual Dividend / Stock Price
0.0%
Last Dividend: N/A
Stock Price: $0.88
Stock Price: $0.88
Payout Ratio (Earnings paid out as dividends)
Dividends Paid / Net Income
—
Dividends Paid: N/A
Net Income: -$429,000
Net Income: -$429,000
Dividends paid not available in cash flow statement
Industry Benchmarks
Compares RDHL against LLM-researched typical ranges for its
industry. One research call per industry, cached indefinitely — every stock in the same industry
reuses the same baseline.
Deep Analysis
Pre-flight intelligence scans the company first, then routes to the right analytical methods.
0
Company Classification
— What type of company is this?
1
Industry Landscape
— Where is the industry headed?
2
Company Momentum
— Where is this company trending?
3
Forward Projection
— 1Y & 2Y projected metrics (requires Layer 1 + 2)
4a
DCF Valuation
— Present value of future cash flows
4b
Earnings Power Value
— Floor value — worth with zero growth
4c
Anchored PE
— Industry PE adjusted for growth differential
4d
Reverse DCF
— What growth is the market pricing in?
4e
Revenue-Based DCF
— For growth/narrative companies (skip if mature earner)
4f
Anchored P/S
— Price-to-Sales peer comparison (skip if mature earner)
4g
Scenario Analysis
— Bull / Base / Bear (skip if mature earner)
4h
Dividend Discount Model
— For dividend/income stocks only
4i
Book Value Analysis
— For deep value / turnaround stocks only
4j
Insider Activity
— Are insiders buying or selling?
4f
Cash Flow Quality
— How trustworthy is the FCF?
4g
Debt Maturity Risk
— Can it handle its debt?
4h
Macro Environment
— Rates, market valuation, volatility
4i
Sector Intelligence
— How does this company compare within its sector?
4j
Revenue Confidence
— How reliable is the growth projection?
4k
Sensitivity Analysis
— How fragile is the fair value estimate?
4l
Sector Demand Cycle
— Is the sector in a boom, steady state, or contraction?
5
AI Investigation
— Adaptive research engine (Claude)
5b
Thesis Evaluation
— What does the market believe? (narrative/platform stocks only)
6
Valuation Synthesis
— Weighted verdict from all methods (requires Layer 4)
Income Statement (Annual)
Last updated: Jun 27, 2026 10:07am (just now)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $85.8M | $61.8M | $6.5M | $8.0M | $286,000 |
| Cost of Revenue | $49.4M | $33.3M | $3.5M | $3.2M | $0 |
| Gross Profit | $36.4M | $28.5M | $3.1M | $4.9M | $286,000 |
| Operating Expenses | $117.5M | $71.3M | -$9.6M | $19.5M | $8.2M |
| Operating Income | -$81.1M | -$42.8M | $12.6M | -$14.6M | -$7.9M |
| Net Income | -$97.7M | -$71.7M | $23.9M | -$8.3M | $-429,000 |
| EBITDA | -$63.0M | -$22.2M | $26.3M | -$7.6M | -$7.7M |
| EPS | $-1,000.00 | $-600.00 | $46.00 | $-7.00 | $0.00 |
| EPS (Diluted) | — | — | — | — | — |
Balance Sheet (Annual)
Last updated: Jun 27, 2026 10:07am (just now)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $29.5M | $20.0M | $5.6M | $4.6M | $4.0M |
| Total Current Assets | $89.2M | $85.9M | $16.1M | $11.9M | $6.5M |
| Total Assets | $181.2M | $158.9M | $23.0M | $18.0M | $25.3M |
| Current Liabilities | $81.5M | $197.5M | $19.2M | $22.2M | $19.2M |
| Long-Term Debt | $83.6M | $0 | $0 | $0 | $0 |
| Total Liabilities | $172.3M | $207.3M | $21.0M | $22.7M | $21.1M |
| Total Equity | $8.9M | -$48.4M | $2.1M | -$4.7M | $4.3M |
| Retained Earnings | -$367.9M | -$433.9M | -$407.7M | -$414.8M | -$413.8M |
Cash Flow (Annual)
Last updated: Jun 27, 2026 10:07am (just now)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$65.0M | -$29.2M | -$35.8M | -$9.4M | -$9.7M |
| Capital Expenditure | $-115,000 | $-198,000 | $-11,000 | $-9,000 | $-5,000 |
| Free Cash Flow | -$65.2M | -$29.4M | -$35.8M | -$9.4M | -$9.7M |
| Acquisitions (net) | $8.0M | $0 | $0 | $0 | $2.0M |
| Debt Repayment | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | $0 | $0 | $0 | $0 | $0 |
| Net Change in Cash | $179,000 | -$9.5M | -$14.4M | $-952,000 | $-646,000 |
Analyst Estimates (Annual)
Last updated: Jun 27, 2026 10:07am (just now)| Metric | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Revenue |
$9.0M $9.0M – $9.0M
|
$20.8M $20.8M – $20.8M
|
$38.0M $38.0M – $38.0M
|
$50.6M $50.6M – $50.6M
|
| EBITDA |
-$53.9M -$64.7M – -$43.1M
|
-$8.5M -$8.5M – -$8.5M
|
-$15.5M -$15.5M – -$15.5M
|
-$20.6M -$20.6M – -$20.6M
|
| Net Income |
-$69.2M -$83.1M – -$55.4M
|
-$126.4M -$126.4M – -$126.4M
|
-$31.6M -$31.6M – -$31.6M
|
$0 |
| EPS | — | — | — | — |
Growth Trends (YoY %)
Last updated: Jun 27, 2026 10:07am (just now)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | -27.9% | -89.4% | +23.2% | -96.4% |
| Gross Profit Growth | -21.7% | -89.2% | +58.0% | -94.1% |
| Operating Income Growth | +47.2% | +129.5% | -215.7% | +45.9% |
| Net Income Growth | +26.7% | +133.4% | -134.6% | +94.8% |
| EBITDA Growth | +64.8% | +218.4% | -128.9% | -0.8% |
Insider Trading (Recent)
Type codes
PPurchase
SSale
AAward / grant
MOption exercise
FIn-kind (tax)
CConversion
GGift
DReturn to issuer
All SEC Form 4 codes
Open market
- P Purchase
- Open-market or private purchase of shares.
- S Sale
- Open-market or private sale of shares.
Compensation (Rule 16b-3)
- A Award / grant
- Grant or award of securities (RSUs, options, etc.) under Rule 16b-3.
- D Return to issuer
- Securities disposed back to the company under Rule 16b-3.
- F In-kind (tax)
- Shares withheld or delivered to pay the option-exercise price or tax — not an open-market sale.
- I Discretionary
- Discretionary transaction under an employee plan — Rule 16b-3(f).
- M Option exercise
- Exercise or conversion of a derivative (option/RSU) into shares — exempt.
Derivatives
- C Conversion
- Conversion of a derivative security into the underlying shares.
- E Short expiration
- Expiration of a short derivative position.
- H Long expiration
- Expiration or cancellation of a long derivative position with value received.
- O OTM exercise
- Exercise of an out-of-the-money derivative.
- X ITM exercise
- Exercise of an in-the-money or at-the-money derivative.
Other exempt
- G Gift
- Bona fide gift of securities.
- L Small acquisition
- Small acquisition under Rule 16a-6.
- W Inheritance
- Acquisition or disposition by will or the laws of descent.
- Z Voting trust
- Deposit into or withdrawal from a voting trust.
Other
- J Other
- Other acquisition or disposition (explained in a Form 4 footnote).
- K Equity swap
- Transaction in an equity swap or similar instrument.
- U Tender / buyout
- Disposition via tender of shares in a change-of-control transaction.
Compensation-plan codes (A, D, F, M) are routine and rarely directional. Open-market P (buy) and S (sale) carry the most signal.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| 2026-04-06 | Raday Gilead | S-Sale | 15,740,000.00 | $0.00 | $1,574 |
| 2026-04-06 | Raday Gilead | M-Exempt | 30,780,000.00 | $0.00 | $0 |
| 2026-03-18 | Tsimchi Ofer | 0.00 | $0.00 | $0 | |
| 2026-03-18 | Tsimchi Ofer | 36,440,000.00 | $0.00 | $0 | |
| 2026-03-18 | Tsimchi Ofer | 180,000.00 | $0.00 | $0 | |
| 2026-03-18 | Scruggs Rick D | 0.00 | $0.00 | $0 | |
| 2026-03-18 | Scruggs Rick D | 73,640,000.00 | $0.00 | $0 | |
| 2026-03-18 | Scruggs Rick D | 840,000.00 | $0.00 | $0 | |
| 2026-03-18 | Reed Kenneth | 0.00 | $0.00 | $0 | |
| 2026-03-18 | Reed Kenneth | 25,830,000.00 | $0.00 | $0 | |
| 2026-03-18 | Reed Kenneth | 250,000.00 | $0.00 | $0 | |
| 2026-03-18 | Raday Gilead | 0.00 | $0.00 | $0 | |
| 2026-03-18 | Raday Gilead | 45,370,000.00 | $0.00 | $0 | |
| 2026-03-18 | Raday Gilead | 180,000.00 | $0.00 | $0 | |
| 2026-03-18 | Mamluk Roni | 0.00 | $0.00 | $0 | |
| 2026-03-18 | Mamluk Roni | 613,500,000.00 | $0.00 | $0 | |
| 2026-03-18 | Ingber Razi | 0.00 | $0.00 | $0 | |
| 2026-03-18 | Ingber Razi | 66,910,000.00 | $0.00 | $0 | |
| 2026-03-18 | Ingber Razi | 230,000.00 | $0.00 | $0 | |
| 2026-03-18 | Goldberg Guy Joel | 0.00 | $0.00 | $0 |
Narrative Economics
The story the market is telling about this stock — the intangible X-factor
(founder mythology, cult dynamics, TAM-of-imagination) that moves price beyond
what cash flows alone explain. After Shiller, Narrative Economics.
No narrative profile yet for RDHL — it's generated by the pipeline (
market-narrative step).
No community reviews yet for RDHL.
Be the first — hit How to Contribute, have any AI review this page, and paste its take back here.
My Notes
personal — only you see this
Sign in to save personal notes and rate your interest in this stock.
Data via Financial Modeling Prep · Cached for performance · fmp
v1.1.352 · d1100787 · 2026-06-26 11:39:30